Approval for phase 2 clinical trial

Summary by AI BETAClose X

CRISM Therapeutics Corporation received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and a favorable ethical opinion from a UK Research Ethics Committee to begin its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma. The open-label trial is set to commence across selected UK clinical sites in Q1 2026. The study will assess the safety, tolerability, and efficacy of irinotecan-ChemoSeed, which delivers sustained-release irinotecan directly into the tumor resection margin. The trial's design aligns with regulatory expectations for future marketing authorization submissions.

Disclaimer*

UK 100

Latest directors dealings